The latest news from the global pharmaceutical industry. Below you will find news and information to keep you up-to-date with what is happening in your industry. Coverage includes regulatory approvals, recall announcements, mergers and acquisitions, personnel news and appointments, new facility and facility expansion updates, collaborations and agreements, and financial updates.
Wednesday, October 06, 2021
Dynavax has executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG ...
read more
Tuesday, October 05, 2021
AstraZeneca has submitted a request to the FDA for an Emergency Use Authorization (EUA) for AZD7442, its long-acting antibody (LAAB) combination, for ...
read more
Thursday, September 30, 2021
Takeda and JCR Pharmaceuticals announced a geographically-focused exclusive collaboration and license agreement to commercialize JR-141 (INN: ...
read more
Thursday, September 30, 2021
Sunovion Pharmaceuticals, its parent company Sumitomo Dainippon Pharma Co and Otsuka Pharmaceutical Co announced today that the companies have entered...
read more
Thursday, September 30, 2021
REGEN-COV significantly reduced viral load in patients hospitalized with COVID-19 who entered the trial without having mounted their own antibody ...
read more
Thursday, September 30, 2021
Eisai and Biogen announced that Eisai has initiated a rolling submission to the FDA of a Biologics License Application (BLA) for lecanemab (BAN2401), ...
read more
Thursday, September 30, 2021
Regeneron Pharmaceuticals announced that the FDA has accepted for priority review the supplemental Biologics License Application (sBLA) for PD-1 ...
read more
Wednesday, September 29, 2021
Merck announced that the Phase 3 KEYNOTE-394 trial investigating KEYTRUDA in Asian patients with advanced hepatocellular carcinoma (HCC) previously ...
read more
Wednesday, September 29, 2021
Bristol Myers Squibb announced that the FDA has accepted the supplemental Biologics License Applications (sBLA) for both Opdivo® (nivolumab) in ...
read more
Thursday, September 23, 2021
Cantargia AB announced that the FDA has granted Orphan Drug Designation in the US to nadunolimab (CAN04) for the treatment of pancreatic cancer. This ...
read more
Thursday, September 23, 2021
Bristol Myers Squibb announced that the FDA has accepted for priority review the Biologics License Application (BLA) for the LAG-3-blocking antibody ...
read more
Thursday, September 23, 2021
AbbVie announced that it has submitted an application to the FDA seeking approval for risankizumab-rzaa (600 mg intravenous (IV) induction and 360 mg ...
read more
Thursday, September 23, 2021
Alvotech, a multinational biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets, ...
read more
Thursday, September 23, 2021
Eli Lilly and Company announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivimab and ...
read more
Thursday, September 23, 2021
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-...
read more